Suppr超能文献

相似文献

1
MELD exceptions for portopulmonary hypertension: current policy and future implementation.
Am J Transplant. 2014 Sep;14(9):2081-7. doi: 10.1111/ajt.12783. Epub 2014 Jul 1.
2
Predictors of Waitlist Mortality in Portopulmonary Hypertension.
Transplantation. 2017 Jul;101(7):1609-1615. doi: 10.1097/TP.0000000000001666.
3
Temporal Trends in Portopulmonary Hypertension Model for End-stage Liver Disease Exceptions and Outcomes.
Transplant Direct. 2022 Nov 11;8(12):e1410. doi: 10.1097/TXD.0000000000001410. eCollection 2022 Dec.
5
Waitlist Outcomes in Liver Transplant Candidates with High MELD and Severe Hepatic Encephalopathy.
Dig Dis Sci. 2018 Jun;63(6):1647-1653. doi: 10.1007/s10620-018-5032-5. Epub 2018 Apr 2.
6
Regional Variation in Appropriateness of Non-Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception.
J Am Coll Surg. 2020 Apr;230(4):503-512.e8. doi: 10.1016/j.jamcollsurg.2019.12.022. Epub 2020 Jan 31.
8
MELD Exceptions and Rates of Waiting List Outcomes.
Am J Transplant. 2011 Nov;11(11):2362-71. doi: 10.1111/j.1600-6143.2011.03735.x. Epub 2011 Sep 15.
10
Outcomes of liver transplantation for porto-pulmonary hypertension in model for end-stage liver disease era.
Dig Dis Sci. 2014 Aug;59(8):1976-82. doi: 10.1007/s10620-014-3065-y. Epub 2014 Feb 21.

引用本文的文献

1
Pulmonary Assessment of the Liver Transplant Recipient.
J Clin Exp Hepatol. 2023 Sep-Oct;13(5):895-911. doi: 10.1016/j.jceh.2023.04.003. Epub 2023 Apr 18.
2
Temporal Trends in Portopulmonary Hypertension Model for End-stage Liver Disease Exceptions and Outcomes.
Transplant Direct. 2022 Nov 11;8(12):e1410. doi: 10.1097/TXD.0000000000001410. eCollection 2022 Dec.
4
Portopulmonary Hypertension: From Bench to Bedside.
Front Med (Lausanne). 2020 Nov 3;7:569413. doi: 10.3389/fmed.2020.569413. eCollection 2020.
5
Hepatopulmonary Syndrome and Portopulmonary Hypertension: Current Status and Implications for Liver Transplantation.
Curr Hepatol Rep. 2020 Sep;19(3):174-185. doi: 10.1007/s11901-020-00532-y. Epub 2020 Jul 11.
6
Hepatopulmonary Syndrome and Portopulmonary Hypertension: The Pulmonary Vascular Enigmas of Liver Disease.
Clin Liver Dis (Hoboken). 2020 Mar 2;15(Suppl 1):S13-S24. doi: 10.1002/cld.846. eCollection 2020 Feb.
8
Portopulmonary Hypertension: A Survey of Practice Patterns and Provider Attitudes.
Transplant Direct. 2019 May 22;5(6):e456. doi: 10.1097/TXD.0000000000000900. eCollection 2019 Jun.
9
The Intersection of Pulmonary Hypertension and Solid Organ Transplantation.
Methodist Debakey Cardiovasc J. 2016 Oct-Dec;12(4 Suppl):10-13. doi: 10.14797/mdcj-12-4s1-10.
10
Predictors of Waitlist Mortality in Portopulmonary Hypertension.
Transplantation. 2017 Jul;101(7):1609-1615. doi: 10.1097/TP.0000000000001666.

本文引用的文献

1
4
Pulmonary vascular complications of liver disease.
Am J Respir Crit Care Med. 2013 Jan 15;187(2):133-43. doi: 10.1164/rccm.201209-1583CI. Epub 2012 Nov 15.
5
Lack of standardization in exception points for patients with primary sclerosing cholangitis and bacterial cholangitis.
Am J Transplant. 2012 Jun;12(6):1603-9. doi: 10.1111/j.1600-6143.2011.03969.x. Epub 2012 Feb 15.
9
Disparities in liver transplantation before and after introduction of the MELD score.
JAMA. 2008 Nov 26;300(20):2371-8. doi: 10.1001/jama.2008.720.
10
Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups.
Am J Transplant. 2008 Nov;8(11):2445-53. doi: 10.1111/j.1600-6143.2008.02384.x. Epub 2008 Sep 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验